Diferencia clínica y Calidad de vida, entre Hilano GF- 20 vs corticoesteroide intra-articular en pacientes con osteoartrosis de rodilla
Abstract
BACKGROUND: Osteoarthritis (OA) is a combination of mechanical and biological factors, alters the articular cartilage, subchondral bone, joint capsule and structures near the joint. Knee OA accounts for up to 80% of OA cases. At the ISSSTE Pachuca Hospital, Dr. Rivera Columba O., knee OA is the second cause of attention of the traumatology and orthopedics service
OBJECTIVE: to show the difference in clinical response and improvement in quality of life between intra-articular use of Hilanum GF-20 and corticosteroid, both part of the basic picture of the ISSSTE
MATERIAL AND METHODS: study that was carried out with a total of 220 patients, first group 140 patients receive Hilano GF-20 three doses, second group 80 patient receives single dose of corticosteroid, WOMAC questionnaire (Western Ontario and McMaster Osteoarthritis Index Score) was performed before and after treatment to assess pain, stiffness and functionality.
RESULTS: in this study, improvement in stiffness and functionality was observed with the use of Hilanum GF-20, in pain control advantageous corticosteroid, however hardly achieved sustained analgesic effect above 3 months.
CONCLUSIONS: In this study it was demonstrated that the Hilanum GF-20 and intraarticular corticosteroids, when used in knee osteoarthritis represent a clinical improvement, in this way we can take resources provided by the institutions in which we work to offer a suitable treatment for this type of patients
Downloads
References
Ayhan E, Kesmezacar H, Akgun I. Intraarticular injections (corticosteroid, hyaluronic acid, platelet rich plasma) for the knee osteoarthritis. Mundo J. Orthop. 2014; 5(3):351-61.
Espinosa R, Arce CA, Cajigas JC. Reunión multidisciplinaria de expertos para el diagnóstico y tratamiento de la osteoartritis: actualización basada en la evidencia. Med. Int. Mex. 2013; 29(1):67-94.
Singh AK, Kalaivani M, Krishnan A. Prevalence of Osteoarthritis of Knee Among Elderly Persons in Urban Slums Using American College of Rheumatology (ACR) Criteria J. Clin. Diagn. Res. 2014; 8(9):JC09-11.
Hunter DJ. Viscosupplementation for osteoarthritis of the knee. N. Engl. J. Med. 2015;372(11):1040-7
A. Oteo Álvaro. Mecanismos etiopatogénicos de la artrosis. Rev. Soc. Esp. Dolor. 2021; 28 (1).
Solis U, Johana S, Bejarano C. Comorbidities and quality of life in Osteoarthritis. Rev Cuba. Reumatol. 2018; 1–14.
Hafer JF, Kent JA, Boyer KAPhysical activity and age-related biomechanical risk factors for knee osteoarthritis. Gait Posture. 2019;70:24-29
De la Garza J, Vazquez E, Aguilar T, Montiel A. Gonzalez A. Calidad de vida en paciente con limitación funcional de la rodilla por gonartrosis. En una unidad de primer nivel de atención médica. Acta ortopédica mex. 2013; 3:27:367-70
Leopold SS, Red BB, Warme WJ, Wherle PA, Pettisp D, Shott S. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial. J. Bone Joint Surg. Am. 2003l;85(7):1197-203.
Instituto Mexicano del Seguro Social [Internet]. Guía de Referencia Rápida Diagnóstico y Tratamiento de Osteoartrosis de Rodilla [30 Enero 2024]. Gob.mx. Available from: http://inger.gob.mx/pluginfile.php/96260/mod_resource/content/355/Archivos/Dip_MeB3stico%20y%20tratamiento%20de%20la%20osteoartritis.pdf
Malemud CJ. Cytokines as therapeutic targets for osteoarthritis. BioDrugs. 2004;18(1):23-35
Jüni P, Hari R, Rutjes AW, Fischer R, Silletta MG, Reichenbach S, da Costa BR. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst. Rev. 2015(10):CD005328.
Wang Y, Hall S, Hanna F, Wluka AE, Grant G, Marks P, et al. Effects of Hylan G-F 20 supplementation on cartilage preservation detected by magnetic resonance imaging in osteoarthritis of the knee: a two-year single-blind clinical trial. BMC Musculoskelet Disord. 2011;12:195
Migliore A, Giovannangeli F, Granata M, Laganà B. Hylan G-F 20: Review of its Safety and Efficacy in the Management of Joint Pain in Osteoarthritis. Clin. Med. Insights Artritis Musculoesquelética Disord. 2010;3:55-68.
Van den Bekerom MPJ, Rys B, Mulier M. Viscosupplementation in the hip: evaluation of hyaluronic acid formulations. Arch. Orthop. Trauma. Surg. 2008;128:275-80.
Migliore A, Bizzi E, Massafra U. The impact of treatment with hylan G-F 20 on progression to total hip arthroplasty in patients with symptomatic hip OA: a retrospective study. Curr. Med. Res. Opin. 2012; 28(5):75560.
Toloza H, Castro D, Rodriguez V, Nordenflycht D. Hialuronato de sodio para osteoartritis de la articulación témporomandibular: Formulaciones disponibles en Chile. Int. J. Odontostomat., 16(3):350-351, 2022.
Bruyère O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) Semin. Arthritis Rheum. 2019; 49(3):337-50.
López S, Martínez C, Romero A. Propiedades métricas del cuestionario WOMAC y de una versión reducida para medir la sintomatología y la discapacidad física. Aten. Primaria. 2009;41(11):613–20
Furuzama J, Muñoz O, Macías S. Effect of polymerized-type I collagen in knee osteoarthritis. II. In vivo study. Eur. J. Clin. Invest. 2009;39:598-606
Bin Abd Razak, Heng H, Cheng K, Mitra A. Correlation between radiographic and arthroscopic findings in Asian osteoarthritic knees. J. Orthop. Surg. 2014;22(2):155-157.
Dowshen S [Internet]. Aspiración articular. Rady Children's [30 Enero 2024] San Diego. 2009. Available from: https://www.rchsd.org/health-articles/aspiracin-articular-artrocentesis/.
Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells Viscosuplementación para el tratamiento de la artrosis de rodilla Cochrane Rev. 2006(2):CD005321.
Copyright (c) 2024 Juan C. Claro-Hernández, José E. Flores-Hernández, Félix G. Mora-Ríos
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
